Unmodified official OCDS data retained by Tenderline for this procurement process.
Complete current OCDS release JSON
{
"id": "003875-2024",
"tag": [
"award",
"contract"
],
"bids": {
"statistics": [
{
"id": "1",
"value": 1,
"measure": "bids",
"relatedLot": "1"
}
]
},
"date": "2024-02-06T13:38:53Z",
"ocid": "ocds-h6vhtk-0425a3",
"buyer": {
"id": "GB-COH-09928547",
"name": "MEDICINES DISCOVERY CATAPULT SERVICES LIMITED"
},
"awards": [
{
"id": "003875-2024-1",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-104454",
"name": "UK Health Security Agency"
}
],
"relatedLots": [
"1"
]
}
],
"tender": {
"id": "ocds-h6vhtk-0425a3",
"lots": [
{
"id": "1",
"status": "cancelled",
"hasOptions": false,
"description": "The UKHSA are well positioned to provide the services required by PACE for PACE portfolio funded projects and the wider AMR community. This will include but not be limited to the following:\nAST against a well characterised (including phenotypically, whole-genome sequenced with full antibiogram data) set of isolates and strains directly relevant to the PACE funding call, and;\nAST data delivered according to industry standards, and;\nProvided in an open-access environment, enabling PACE awardees to directly learn from and access the lab capability provided for onward studies, and;\nAn opportunity to transfer specific isolates to PACE awardee labs for onward studies, and;\nThe isolate bank will be evolved using the latest surveillance and national reference laboratory data on clinical isolates currently circulating nationally and internationally, and;\nUKHSA AMR labs then enable rapid characterisation of new isolates including full antibiogram and whole genome sequencing, and;\nA service model that can account for diverse needs of the PACE-funded projects as they arise i.e. variations to SOPs as required and ability to provide rapid surge capacity as and when needed.",
"awardCriteria": {
"criteria": [
{
"type": "price"
}
]
}
}
],
"items": [
{
"id": "1",
"relatedLot": "1",
"deliveryAddresses": [
{
"region": "UK"
}
],
"additionalClassifications": [
{
"id": "73200000",
"scheme": "CPV",
"description": "Research and development consultancy services"
}
]
}
],
"title": "A multi-drug resistant pathogen reference strain and clinical isolate collection",
"status": "complete",
"coveredBy": [
"GPA"
],
"legalBasis": {
"id": "32014L0024",
"scheme": "CELEX"
},
"description": "A multi-drug resistant pathogen reference strain and clinical isolate collection representative of pathogens and resistance mechanisms directly aligned to the PACE first funding call that can be used by the provider to generate antimicrobial susceptibility data across PACE-funded projects and that can be made available to PACE awardees for onward project progression.\nContinued expansion and characterisation of the strain and isolate collection to ensure it remains reflective of contemporary and genomically diverse multi-drug resistant and epidemic lineages of target pathogens (~20-30 strains) across E. coli, K. pneumoniae, P. aeruginosa, A. baumannii and S. aureus. This expanded collection will be made available for antimicrobial susceptibility testing (AST) across PACE-funded projects and the wider AMR community.",
"classification": {
"id": "73200000",
"scheme": "CPV",
"description": "Research and development consultancy services"
},
"procurementMethod": "limited",
"mainProcurementCategory": "services",
"procurementMethodDetails": "Award procedure without prior publication of a call for competition",
"procurementMethodRationale": "Following the voluntary ex ante transparency (VEAT) notice previously published, indicating that Medicines Discovery Catapult, intends to enter into a contract with the UK Health Security Agency (UKHSA) for a multi-drug resistant pathogen reference strain and clinical isolate collection without a call to competition in accordance with the Public Contracts Regulations 2015 ((32.2(b) ii), Medicines Discovery Catapult has now entered into the contract with UKHSA.\nThe contract is directly aligned to the PACE (Pathways to Antimicrobial Clinical Efficacy) first funding call that can be used by the provider to generate antimicrobial susceptibility data across PACE-funded projects and that can be made available to PACE awardees for onward project progression and will allow continued expansion and characterisation of the strain and isolate collection to ensure it remains reflective of contemporary and genomically diverse multi-drug resistant and epidemic lineages of target pathogens (~20-30 strains) across E. coli, K. pneumoniae, P. aeruginosa, A. baumannii and S. aureus.\nThis expanded collection will be made available for antimicrobial susceptibility testing (AST) across PACE-funded projects and the wider AMR community.\nThe UKHSA maintains unique capabilities and assets that are part of the country's critical national infrastructure to support this aim, this includes;\nThe English surveillance programme for antimicrobial utilisation and resistance (ESPAUR), which identifies emergence and trends in key resistance-causing pathogens.\nThe AMRHAI (antimicrobial resistance and healthcare associated infections) national reference unit, part of the Bacteriology reference department (BRD) - a national and international laboratory reference centre for a bacterial infections.\nThe isolate bank will be evolved using the latest surveillance and national reference laboratory data on clinical isolates currently circulating nationally and internationally and;\nUKHSA AMR labs then enable rapid characterisation of new isolates including full antibiogram and whole genome sequencing.",
"procurementMethodRationaleClassifications": [
{
"id": "D_OUTSIDE_SCOPE",
"scheme": "TED_PT_AWARD_CONTRACT_WITHOUT_CALL",
"description": "The procurement falls outside the scope of application of the directive"
}
]
},
"parties": [
{
"id": "GB-COH-09928547",
"name": "MEDICINES DISCOVERY CATAPULT SERVICES LIMITED",
"roles": [
"buyer"
],
"address": {
"region": "UKD62",
"locality": "MACCLESFIELD",
"postalCode": "SK10 4ZF",
"countryName": "United Kingdom",
"streetAddress": "Block 35g Mereside,Alderley Park"
},
"details": {
"url": "https://md.catapult.org.uk/",
"classifications": [
{
"scheme": "TED_CA_TYPE",
"description": "Drug Discovery / Health"
},
{
"scheme": "COFOG",
"description": "Drug Discovery / Health"
}
]
},
"identifier": {
"id": "09928547",
"scheme": "GB-COH",
"legalName": "MEDICINES DISCOVERY CATAPULT SERVICES LIMITED"
},
"contactPoint": {
"email": "procurement@md.catapult.org.uk"
}
},
{
"id": "GB-FTS-104454",
"name": "UK Health Security Agency",
"roles": [
"supplier"
],
"address": {
"region": "UK",
"locality": "Salisbury",
"countryName": "United Kingdom"
},
"details": {
"scale": "large"
},
"identifier": {
"legalName": "UK Health Security Agency",
"noIdentifierRationale": "notOnAnyRegister"
}
},
{
"id": "GB-FTS-100678",
"name": "Medicines Discovery Catapult",
"roles": [
"reviewBody"
],
"address": {
"locality": "Macclesfield",
"postalCode": "SK10 4ZF",
"countryName": "United Kingdom"
},
"identifier": {
"legalName": "Medicines Discovery Catapult"
}
}
],
"language": "en",
"contracts": [
{
"id": "003875-2024-1",
"value": {
"amount": 695718,
"currency": "GBP"
},
"status": "active",
"awardID": "003875-2024-1",
"dateSigned": "2024-01-02T00:00:00Z"
}
],
"initiationType": "tender"
}Complete JSON history (2 releases)
6 Feb 2024 · 003875-2024 · award, contract
{
"id": "003875-2024",
"tag": [
"award",
"contract"
],
"bids": {
"statistics": [
{
"id": "1",
"value": 1,
"measure": "bids",
"relatedLot": "1"
}
]
},
"date": "2024-02-06T13:38:53Z",
"ocid": "ocds-h6vhtk-0425a3",
"buyer": {
"id": "GB-COH-09928547",
"name": "MEDICINES DISCOVERY CATAPULT SERVICES LIMITED"
},
"awards": [
{
"id": "003875-2024-1",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-104454",
"name": "UK Health Security Agency"
}
],
"relatedLots": [
"1"
]
}
],
"tender": {
"id": "ocds-h6vhtk-0425a3",
"lots": [
{
"id": "1",
"status": "cancelled",
"hasOptions": false,
"description": "The UKHSA are well positioned to provide the services required by PACE for PACE portfolio funded projects and the wider AMR community. This will include but not be limited to the following:\nAST against a well characterised (including phenotypically, whole-genome sequenced with full antibiogram data) set of isolates and strains directly relevant to the PACE funding call, and;\nAST data delivered according to industry standards, and;\nProvided in an open-access environment, enabling PACE awardees to directly learn from and access the lab capability provided for onward studies, and;\nAn opportunity to transfer specific isolates to PACE awardee labs for onward studies, and;\nThe isolate bank will be evolved using the latest surveillance and national reference laboratory data on clinical isolates currently circulating nationally and internationally, and;\nUKHSA AMR labs then enable rapid characterisation of new isolates including full antibiogram and whole genome sequencing, and;\nA service model that can account for diverse needs of the PACE-funded projects as they arise i.e. variations to SOPs as required and ability to provide rapid surge capacity as and when needed.",
"awardCriteria": {
"criteria": [
{
"type": "price"
}
]
}
}
],
"items": [
{
"id": "1",
"relatedLot": "1",
"deliveryAddresses": [
{
"region": "UK"
}
],
"additionalClassifications": [
{
"id": "73200000",
"scheme": "CPV",
"description": "Research and development consultancy services"
}
]
}
],
"title": "A multi-drug resistant pathogen reference strain and clinical isolate collection",
"status": "complete",
"coveredBy": [
"GPA"
],
"legalBasis": {
"id": "32014L0024",
"scheme": "CELEX"
},
"description": "A multi-drug resistant pathogen reference strain and clinical isolate collection representative of pathogens and resistance mechanisms directly aligned to the PACE first funding call that can be used by the provider to generate antimicrobial susceptibility data across PACE-funded projects and that can be made available to PACE awardees for onward project progression.\nContinued expansion and characterisation of the strain and isolate collection to ensure it remains reflective of contemporary and genomically diverse multi-drug resistant and epidemic lineages of target pathogens (~20-30 strains) across E. coli, K. pneumoniae, P. aeruginosa, A. baumannii and S. aureus. This expanded collection will be made available for antimicrobial susceptibility testing (AST) across PACE-funded projects and the wider AMR community.",
"classification": {
"id": "73200000",
"scheme": "CPV",
"description": "Research and development consultancy services"
},
"procurementMethod": "limited",
"mainProcurementCategory": "services",
"procurementMethodDetails": "Award procedure without prior publication of a call for competition",
"procurementMethodRationale": "Following the voluntary ex ante transparency (VEAT) notice previously published, indicating that Medicines Discovery Catapult, intends to enter into a contract with the UK Health Security Agency (UKHSA) for a multi-drug resistant pathogen reference strain and clinical isolate collection without a call to competition in accordance with the Public Contracts Regulations 2015 ((32.2(b) ii), Medicines Discovery Catapult has now entered into the contract with UKHSA.\nThe contract is directly aligned to the PACE (Pathways to Antimicrobial Clinical Efficacy) first funding call that can be used by the provider to generate antimicrobial susceptibility data across PACE-funded projects and that can be made available to PACE awardees for onward project progression and will allow continued expansion and characterisation of the strain and isolate collection to ensure it remains reflective of contemporary and genomically diverse multi-drug resistant and epidemic lineages of target pathogens (~20-30 strains) across E. coli, K. pneumoniae, P. aeruginosa, A. baumannii and S. aureus.\nThis expanded collection will be made available for antimicrobial susceptibility testing (AST) across PACE-funded projects and the wider AMR community.\nThe UKHSA maintains unique capabilities and assets that are part of the country's critical national infrastructure to support this aim, this includes;\nThe English surveillance programme for antimicrobial utilisation and resistance (ESPAUR), which identifies emergence and trends in key resistance-causing pathogens.\nThe AMRHAI (antimicrobial resistance and healthcare associated infections) national reference unit, part of the Bacteriology reference department (BRD) - a national and international laboratory reference centre for a bacterial infections.\nThe isolate bank will be evolved using the latest surveillance and national reference laboratory data on clinical isolates currently circulating nationally and internationally and;\nUKHSA AMR labs then enable rapid characterisation of new isolates including full antibiogram and whole genome sequencing.",
"procurementMethodRationaleClassifications": [
{
"id": "D_OUTSIDE_SCOPE",
"scheme": "TED_PT_AWARD_CONTRACT_WITHOUT_CALL",
"description": "The procurement falls outside the scope of application of the directive"
}
]
},
"parties": [
{
"id": "GB-COH-09928547",
"name": "MEDICINES DISCOVERY CATAPULT SERVICES LIMITED",
"roles": [
"buyer"
],
"address": {
"region": "UKD62",
"locality": "MACCLESFIELD",
"postalCode": "SK10 4ZF",
"countryName": "United Kingdom",
"streetAddress": "Block 35g Mereside,Alderley Park"
},
"details": {
"url": "https://md.catapult.org.uk/",
"classifications": [
{
"scheme": "TED_CA_TYPE",
"description": "Drug Discovery / Health"
},
{
"scheme": "COFOG",
"description": "Drug Discovery / Health"
}
]
},
"identifier": {
"id": "09928547",
"scheme": "GB-COH",
"legalName": "MEDICINES DISCOVERY CATAPULT SERVICES LIMITED"
},
"contactPoint": {
"email": "procurement@md.catapult.org.uk"
}
},
{
"id": "GB-FTS-104454",
"name": "UK Health Security Agency",
"roles": [
"supplier"
],
"address": {
"region": "UK",
"locality": "Salisbury",
"countryName": "United Kingdom"
},
"details": {
"scale": "large"
},
"identifier": {
"legalName": "UK Health Security Agency",
"noIdentifierRationale": "notOnAnyRegister"
}
},
{
"id": "GB-FTS-100678",
"name": "Medicines Discovery Catapult",
"roles": [
"reviewBody"
],
"address": {
"locality": "Macclesfield",
"postalCode": "SK10 4ZF",
"countryName": "United Kingdom"
},
"identifier": {
"legalName": "Medicines Discovery Catapult"
}
}
],
"language": "en",
"contracts": [
{
"id": "003875-2024-1",
"value": {
"amount": 695718,
"currency": "GBP"
},
"status": "active",
"awardID": "003875-2024-1",
"dateSigned": "2024-01-02T00:00:00Z"
}
],
"initiationType": "tender"
}14 Dec 2023 · 036804-2023 · award, contract
{
"id": "036804-2023",
"tag": [
"award",
"contract"
],
"date": "2023-12-14T13:49:41Z",
"ocid": "ocds-h6vhtk-0425a3",
"buyer": {
"id": "GB-COH-09928547",
"name": "MEDICINES DISCOVERY CATAPULT"
},
"awards": [
{
"id": "036804-2023-1",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-100677",
"name": "UK Health Security Agency"
}
],
"relatedLots": [
"1"
]
}
],
"tender": {
"id": "ocds-h6vhtk-0425a3",
"lots": [
{
"id": "1",
"hasOptions": false,
"description": "The UKHSA are well positioned to provide the services required by PACE for PACE portfolio funded projects and the wider AMR community. This will include but not be limited to the following:\nAST against a well characterised (including phenotypically, whole-genome sequenced with full antibiogram data) set of isolates and strains directly relevant to the PACE funding call, and;\nAST data delivered according to industry standards, and;\nProvided in an open-access environment, enabling PACE awardees to directly learn from and access the lab capability provided for onward studies, and;\nAn opportunity to transfer specific isolates to PACE awardee labs for onward studies, and;\nThe isolate bank will be evolved using the latest surveillance and national reference laboratory data on clinical isolates currently circulating nationally and internationally, and;\nUKHSA AMR labs then enable rapid characterisation of new isolates including full antibiogram and whole genome sequencing, and;\nA service model that can account for diverse needs of the PACE-funded projects as they arise i.e. variations to SOPs as required and ability to provide rapid surge capacity as and when needed."
}
],
"items": [
{
"id": "1",
"relatedLot": "1",
"deliveryAddresses": [
{
"region": "UK"
}
]
}
],
"title": "A multi-drug resistant pathogen reference strain and clinical isolate collection",
"status": "complete",
"coveredBy": [
"GPA"
],
"legalBasis": {
"id": "32014L0024",
"scheme": "CELEX"
},
"description": "A multi-drug resistant pathogen reference strain and clinical isolate collection representative of pathogens and resistance mechanisms directly aligned to the PACE first funding call that can be used by the provider to generate antimicrobial susceptibility data across PACE-funded projects and that can be made available to PACE awardees for onward project progression.\nContinued expansion and characterisation of the strain and isolate collection to ensure it remains reflective of contemporary and genomically diverse multi-drug resistant and epidemic lineages of target pathogens (~20-30 strains) across E. coli, K. pneumoniae, P. aeruginosa, A. baumannii and S. aureus. This expanded collection will be made available for antimicrobial susceptibility testing (AST) across PACE-funded projects and the wider AMR community.",
"classification": {
"id": "73200000",
"scheme": "CPV",
"description": "Research and development consultancy services"
},
"procurementMethod": "limited",
"mainProcurementCategory": "services",
"procurementMethodDetails": "Negotiated without publication of a contract notice",
"procurementMethodRationale": "This is a voluntary ex ante transparency (VEAT) notice, indicating that Medicines Discovery Catapult, intends to enter into a contract with the UK Health Security Agency for a multi-drug resistant pathogen reference strain and clinical isolate collection without a call to competition in accordance with the Public Contracts Regulations 2015 ((32.2(b) ii).\nThe contract is directly aligned to the PACE (Pathways to Antimicrobial Clinical Efficacy) first funding call that can be used by the provider to generate antimicrobial susceptibility data across PACE-funded projects and that can be made available to PACE awardees for onward project progression and will allow continued expansion and characterisation of the strain and isolate collection to ensure it remains reflective of contemporary and genomically diverse multi-drug resistant and epidemic lineages of target pathogens (~20-30 strains) across E. coli, K. pneumoniae, P. aeruginosa, A. baumannii and S. aureus. \nThis expanded collection will be made available for antimicrobial susceptibility testing (AST) across PACE-funded projects and the wider AMR community.\nThe UKHSA maintains unique capabilities and assets that are part of the country's critical national infrastructure to support this aim, this includes;\nThe English surveillance programme for antimicrobial utilisation and resistance (ESPAUR), which identifies emergence and trends in key resistance-causing pathogens.\nThe AMRHAI (antimicrobial resistance and healthcare associated infections) national reference unit, part of the Bacteriology reference department (BRD) - a national and international laboratory reference centre for a bacterial infections. \nThe isolate bank will be evolved using the latest surveillance and national reference laboratory data on clinical isolates currently circulating nationally and internationally and;\nUKHSA AMR labs then enable rapid characterisation of new isolates including full antibiogram and whole genome sequencing.",
"procurementMethodRationaleClassifications": [
{
"id": "D_TECHNICAL",
"scheme": "TED_PT_AWARD_CONTRACT_WITHOUT_CALL",
"description": "The works, supplies or services can be provided only by a particular economic operator due to absence of competition for technical reasons"
}
]
},
"parties": [
{
"id": "GB-COH-09928547",
"name": "MEDICINES DISCOVERY CATAPULT",
"roles": [
"buyer"
],
"address": {
"region": "UKD62",
"locality": "MACCLESFIELD",
"postalCode": "SK104ZF",
"countryName": "United Kingdom",
"streetAddress": "Block 35g Mereside,Alderley Park"
},
"details": {
"url": "https://md.catapult.org.uk/",
"classifications": [
{
"scheme": "TED_CA_TYPE",
"description": "Drug Discovery / Health"
},
{
"scheme": "COFOG",
"description": "Drug Discovery / Health"
}
]
},
"identifier": {
"id": "09928547",
"scheme": "GB-COH",
"legalName": "MEDICINES DISCOVERY CATAPULT"
},
"contactPoint": {
"email": "procurement@md.catapult.org.uk"
}
},
{
"id": "GB-FTS-100677",
"name": "UK Health Security Agency",
"roles": [
"supplier"
],
"address": {
"region": "UK",
"locality": "London",
"postalCode": "E14 4PU",
"countryName": "United Kingdom"
},
"details": {
"scale": "large"
},
"identifier": {
"legalName": "UK Health Security Agency",
"noIdentifierRationale": "notOnAnyRegister"
}
},
{
"id": "GB-FTS-100678",
"name": "Medicines Discovery Catapult",
"roles": [
"reviewBody"
],
"address": {
"locality": "Macclesfield",
"postalCode": "SK10 4ZF",
"countryName": "United Kingdom"
},
"identifier": {
"legalName": "Medicines Discovery Catapult"
}
}
],
"language": "en",
"contracts": [
{
"id": "036804-2023-1",
"value": {
"amount": 695718,
"currency": "GBP"
},
"status": "active",
"awardID": "036804-2023-1",
"dateSigned": "2023-11-29T00:00:00Z"
}
],
"initiationType": "tender"
}